Article

Allergan, Molecular Partners enter DARPin agreements

Allergan Inc. and Molecular Partners AG have entered into two agreements to discover, develop, and commercialize proprietary therapeutic designed ankyrin repeat protein (DARPin) products for the treatment of opthalmic diseases.

Irvine, CA, and Zurich-Schlieren, Switzerland-Allergan Inc. and Molecular Partners AG have entered into two agreements to discover, develop, and commercialize proprietary therapeutic designed ankyrin repeat protein (DARPin) products for the treatment of ophthalmic diseases.

DARPins are genetically engineered antibody mimetic proteins that exhibit highly specific and high-affinity target protein binding. The non-immunoglobulin proteins have shown promise over antibodies for target binding in drug discovery and development.

The first agreement is an exclusive license agreement for the design, development, and commercialization of MP0260, a dual anti-vascular endothelial growth factor (VEGF)-A/platelet-derived growth factor (PDGF)-B DARPin, and its corresponding backups for the treatment of exudative age-related macular degeneration (AMD) and related conditions. Under the license agreement, Allergan and Molecular Partners will work together to develop MP0260 through human proof of concept, at which point Molecular Partners has the option to co-fund Allergan's development costs in exchange for a significant royalty step up.

The second agreement is an exclusive discovery alliance agreement under which the companies will collaborate to design and develop DARPins against selected targets that are implicated in causing serious diseases of the eye. During the research phase, Allergan has the right to exercise three options to license collaboration compounds for ophthalmology exclusively. On execution of each option, Allergan will pay Molecular Partners an option exercise fee and be solely responsible for all downstream development, manufacturing, and commercialization activities.

Molecular Partners will receive combined upfront payments of $62.5 million under the two agreements and is eligible to receive additional success-based payments, including up to $1.4 billion in aggregate development, regulatory, and sales milestones, and tiered royalties for future product sales.

For more articles in this issue of Ophthalmology Times eReport, click here.

"Uveitis agent granted orphan drug status"&nbsp&nbspNext>>

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.